Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline and Omega-3 in ARMS
NCT02569307Phase 2Completed
- Sponsor
- Pakistan Institute of Living and Learning
- Start
- Oct 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of minocycline and omega-3 fatty acid in psychotic disorder (4 arms), sponsored by Pakistan Institute of Living and Learning. Primary endpoint: Transition to psychotic disorder at 12 months. Started Oct 2015; status: completed.
02
Drugs
minocyclineomega-3 fatty acid
03
Conditions
psychotic disorder
Beyond the preview
Go deeper on NCT02569307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569307.